The Children’s Cancer Therapy Development Institute (cc-TDI) is proud to announce a new publication, DNA methylation patterns are influenced by Pax3::Foxo1 expression and developmental lineage
This holiday season, we recognize the promise that our research holds for childhood cancer heroes and their families. And at cc-TDI, the parent partnership is
Be part of our team, uncovering how childhood cancers work – and helping find the treatments that could go to clinical trials to improve outcomes.
The Children’s Cancer Therapy Development Institute (cc-TDI) has been awarded $222,120 by the Megan’s Mission Foundation to advance three clinical research initiatives focused on Rhabdomyosarcoma
This month, we invite you to join us in supporting pioneering research at cc-TDI, which has served as a beacon of hope for families like ours. Our
In a groundbreaking study, Entinostat as a combinatorial therapeutic for rhabdomyosarcoma, published earlier this week in Scientific Reports, researchers with the Children’s Cancer Therapy Development
The Children’s Cancer Therapy Development Institute (cc-TDI) is delighted to welcome former Intel Executive, Claire Newman, as their new Executive Director on July 1st. Claire
The Hundt Strong golf outing began in 2017 as a way to support Billy Hundt during his extensive treatment for rhabdomyosarcoma (RMS). From that very
On Monday, May 13th, joined by dear supporters and friends, cc-TDI virtually celebrated the one-year anniversary of our new laboratory. Thanks to incredible support over
In March the Children’s Cancer Therapy Development Institute (cc-TDI) announced its partnership with Team KOODAC (Knock Out Oncogenic Drivers and Curing Childhood Cancer), a global
We are thrilled to present the 2023 inaugural Impact Report for the Children’s Cancer Therapy Development Institute (cc-TDI), a testament to our joint commitment to advancing childhood
We proudly announce our global Artificial Intelligence (AI) collaboration with Atomwise, resulting in a new publication in the journal Scientific Reports. The paper, “AI is
In a significant stride towards advancing pediatric cancer research, we are thrilled to announce that the state of Oregon has allocated a generous $1 million
The Children’s Cancer Therapy Development Institute (cc-TDI) proudly announces its partnership with Team KOODAC (Knock Out Oncogenic Drivers and Curing Childhood Cancer), a global interdisciplinary
We are excited to update you on entinostat, a therapy that’s traveled through cc-TDI’s development pipeline in the fight against rhabdomyosarcoma (RMS). Entinostat is a breast
Are you a PhD developmental biologist, biochemist, molecular biologist, biomedical engineer or stem cell biologist interested in changing paradigms and outcomes for cancers of children,
cc-TDI welcomed Claire Newman to cc-TDI as a Social Venture Partners Encore Fellow in August 2023. Claire’s role in Operations Scaling and Optimization includes diving
The Silicon Forest in Hillsboro, OR, January 9, 2024 – The Children’s Cancer Therapy Development Institute was awarded $100,000 in continued support of two research
As we make our final approach to the new year, we want to share a story that embodies the #givingbackchildhood spirit of cc-TDI’s mission. Meet
In August 2023, the cc-TDI team was introduced to the Bliss family, a vibrant and loving family who wanted to make a difference in the
The Children’s Cancer Therapy Development Institute (cc-TDI) is proud to announce a new publication, DNA methylation patterns are influenced by Pax3::Foxo1 expression and developmental lineage
This holiday season, we recognize the promise that our research holds for childhood cancer heroes and their families. And at cc-TDI, the parent partnership is
Be part of our team, uncovering how childhood cancers work – and helping find the treatments that could go to clinical trials to improve outcomes.
The Children’s Cancer Therapy Development Institute (cc-TDI) has been awarded $222,120 by the Megan’s Mission Foundation to advance three clinical research initiatives focused on Rhabdomyosarcoma
This month, we invite you to join us in supporting pioneering research at cc-TDI, which has served as a beacon of hope for families like ours. Our
In a groundbreaking study, Entinostat as a combinatorial therapeutic for rhabdomyosarcoma, published earlier this week in Scientific Reports, researchers with the Children’s Cancer Therapy Development
The Children’s Cancer Therapy Development Institute (cc-TDI) is delighted to welcome former Intel Executive, Claire Newman, as their new Executive Director on July 1st. Claire
The Hundt Strong golf outing began in 2017 as a way to support Billy Hundt during his extensive treatment for rhabdomyosarcoma (RMS). From that very
On Monday, May 13th, joined by dear supporters and friends, cc-TDI virtually celebrated the one-year anniversary of our new laboratory. Thanks to incredible support over
In March the Children’s Cancer Therapy Development Institute (cc-TDI) announced its partnership with Team KOODAC (Knock Out Oncogenic Drivers and Curing Childhood Cancer), a global
We are thrilled to present the 2023 inaugural Impact Report for the Children’s Cancer Therapy Development Institute (cc-TDI), a testament to our joint commitment to advancing childhood
We proudly announce our global Artificial Intelligence (AI) collaboration with Atomwise, resulting in a new publication in the journal Scientific Reports. The paper, “AI is
In a significant stride towards advancing pediatric cancer research, we are thrilled to announce that the state of Oregon has allocated a generous $1 million
The Children’s Cancer Therapy Development Institute (cc-TDI) proudly announces its partnership with Team KOODAC (Knock Out Oncogenic Drivers and Curing Childhood Cancer), a global interdisciplinary
We are excited to update you on entinostat, a therapy that’s traveled through cc-TDI’s development pipeline in the fight against rhabdomyosarcoma (RMS). Entinostat is a breast
Are you a PhD developmental biologist, biochemist, molecular biologist, biomedical engineer or stem cell biologist interested in changing paradigms and outcomes for cancers of children,
cc-TDI welcomed Claire Newman to cc-TDI as a Social Venture Partners Encore Fellow in August 2023. Claire’s role in Operations Scaling and Optimization includes diving
The Silicon Forest in Hillsboro, OR, January 9, 2024 – The Children’s Cancer Therapy Development Institute was awarded $100,000 in continued support of two research
As we make our final approach to the new year, we want to share a story that embodies the #givingbackchildhood spirit of cc-TDI’s mission. Meet
In August 2023, the cc-TDI team was introduced to the Bliss family, a vibrant and loving family who wanted to make a difference in the
EIN: 46-5759569
cc-TDI is a qualified 501(c)(3) charitable organization registered with the IRS
(consult with a CPA regarding specific tax implications)
Copyright 2024 – Children’s Cancer Therapy Development Institute